✦ LIBER ✦

1203 SAFETY PROFILE OF DACLATASVIR IN COMBINATION WITH PEGINTERFERON alfa AND RIBAVIRIN IN 1100 PATIENTS WITH CHRONIC HCV INFECTION TREATED IN PHASE 2 STUDIES

✍ Scribed by Jacobson, I.; Dimitrova, D.; Hughes, E.A.; Yin, P.D.; Mendez, P.; Yogendran, L.; Schnittman, S.

Book ID: 123167110
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 53 KB
Volume: 58
Category: Article
ISSN: 0168-8278
DOI: 10.1016/S0168-8278(13)61204-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

1193 A DESCRIPTION OF VIROLOGIC ESCAPE I

1193 A DESCRIPTION OF VIROLOGIC ESCAPE IN HCV GENOTYPE 1-INFECTED PATIENTS TREATED WITH DACLATASVIR (BMS-790052) IN COMBINATION WITH RIBAVIRIN AND PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B

✍ McPhee, F.; Hernandez, D.; Yu, F.; Ueland, J.; Chayama, K.; Toyota, J.; Izumi, N 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 56 KB

1418 DACLATASVIR COMBINED WITH PEGINTERF

1418 DACLATASVIR COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN FOR 12 OR 16 WEEKS IN PATIENTS WITH HCV GENOTYPE 2 OR 3 INFECTION: COMMAND GT2/3 STUDY

✍ Dore, G.J.; Lawitz, E.; H'ezode, C.; Shafran, S.; Ramji, A.; Tatum, H.; Taliani, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 78 KB

Ultradeep Sequencing Study of Chronic He

Ultradeep Sequencing Study of Chronic Hepatitis C Virus Genotype 1 Infection in Patients Treated with Daclatasvir, Peginterferon, and Ribavirin

✍ Murakami, E.; Imamura, M.; Hayes, C. N.; Abe, H.; Hiraga, N.; Honda, Y.; Ono, A. 📂 Article 📅 2014 🏛 American Society for Microbiology 🌐 English ⚖ 790 KB

85 ANTIVIRAL ACTIVITY AND SAFETY OF ITMN

85 ANTIVIRAL ACTIVITY AND SAFETY OF ITMN-191 IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV)

✍ N. Forestier; D. Larrey; P. Marcellin; Y. Benhamou; D. Guyader; W. Bradford; S. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 51 KB

804 EXPOSURE–RESPONSE ANALYSES OF ASUNAP

804 EXPOSURE–RESPONSE ANALYSES OF ASUNAPREVIR IN COMBINATION WITH DACLATASVIR PEGINTERFERON/ RIBAVIRIN AMONG PATIENTS WITH GENOTYPE 1 CHRONIC HCV INFECTION: DOSE SELECTION FOR PHASE 3 CLINICAL TRIALS

✍ Chan, P.; Tafoya, E.; Eley, T.; He, B.; Mendez, P.; Gardiner, D.; Hughes, E.; Sc 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 72 KB

Clinical trial: exposure to ribavirin pr

Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alfa-2a plus ribavirin

✍ V. G. BAIN; S. S. LEE; K. PELTEKIAN; E. M. YOSHIDA; M. DESCHÊNES; M. SHERMAN; R. 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 167 KB